Supreme Court Rejects CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising clash with genetic testing firm Natera.
The U.S. Supreme Court on Monday refused to take up an appeal filed by CareDx in its ongoing false-advertising legal battle with Natera, Inc. (NTRA), leaving a lower court's ruling intact and dealing a significant procedural setback to the transplant diagnostics company. The high court's decision not to intervene marks a critical juncture in a dispute that has drawn attention across the genetic testing and diagnostics industry.
The case centers on accusations of false advertising between two competitors in the molecular diagnostics space, where CareDx and Natera have clashed over marketing claims related to their respective organ transplant rejection testing products. By declining to hear CareDx's appeal, the Supreme Court effectively allows the previous ruling against CareDx to stand without further federal review at the nation's highest judicial level.
Read more Intel Stock Up 550% But Manufacturing Hurdles Remain →
For Natera, the development represents a meaningful legal victory that could bolster its competitive position in the transplant testing market. Investors and analysts tracking NTRA shares are likely to view the Supreme Court's refusal as a stabilizing signal for Natera's legal outlook, reducing uncertainty around one of the more prominent litigation risks the company has faced in recent years.
For CareDx, the road ahead may involve compliance with prior court mandates or alternative legal strategies short of Supreme Court intervention. The rejection underscores the difficulty companies face when attempting to escalate commercial litigation to the nation's highest court, which accepts only a small fraction of petitions each term. The outcome could influence how both firms position their products and marketing strategies going forward.
Continue reading at Yahoo Finance.
